PCSK9 and atherosclerosis: Despite genetic studies (78) and post hoc analysis of landmark statin (8) and PCSK9 trials (85) suggesting a lower risk of ASCVD with reduced TG, the results from pharmacologically achieved lower TG levels with niacin, fibrates and omega-3 FA have been inconsistent.